Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT07575984

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
  • Pharmasoft Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07575984
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07575984. Randomized; no masking; primary purpose treatment. Start 2025-11-04 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke
Intervention (Drug)
Mexidol
Intervention (Drug)
Glycine
Lead sponsor
Pharmasoft (class: industry)

Record details

Record id
cardio:ct-nct07575984
Content hash
38307a89e57a63958e96f497e2c405d9c3cf38a169db388076e3e19b96edac2f